Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Johnson

Showing results (151-160 of 170) with videos related to

Pageof 17
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2019
A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancerNatasha C Lucki, Genaro R Villa, Naja Vergani, et al.
Diabetes|October 9, 2013
Podocyte-specific GLUT4-deficient mice have fewer and larger podocytes and are protected from diabetic nephropathyJohanna Guzman, Alexandra N Jauregui, Sandra Merscher-Gomez, et al.
Journal of the American Chemical Society|July 1, 2024
On Demand Bioorthogonal Switching of an Antibody-Conjugated SPECT Probe to a Cytotoxic Payload: from Imaging to TherapyPragya Adhikari, Guangmin Li, MaryAnn Go, et al.
NAM Perspectives|September 30, 2022
The Promise of Digital Health: Then, Now, and the FutureAmy Abernethy, Laura Adams, Meredith Barrett, et al.
Neuron|November 5, 2020
A Non-covalent Ligand Reveals Biased Agonism of the TRPA1 Ion ChannelChang Liu, Rebecca Reese, Simon Vu, et al.
Journal of Medicinal Chemistry|July 20, 2016
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung CancersGérald Lelais, Robert Epple, Thomas H Marsilje, et al.
NAM Perspectives|November 2, 2023
Identifying Credible Sources of Health Information in Social Media: Phase 2-Considerations for Non-Accredited Nonprofit Organizations, For-Profit Entities, and Individual SourcesHelen Burstin, Susan Curry, Megan L Ranney, et al.
Journal of Medicinal Chemistry|March 27, 2014
Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacyDean P Phillips, Wenqi Gao, Yang Yang, et al.
Journal of Medicinal Chemistry|November 21, 2017
The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic PropertiesTony Siu, Jason Brubaker, Peter Fuller, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 17, 2025
In an older-age vascular cohort, carotid stenosis is associated with processing speed and executive function cognitive deficits, which correlate with p-tau217Summan Zahra, Scott R French, Juan C Arias, et al.
Pageof 17

Showing results (151-160 of 170) with videos related to

Sort By:
Pageof 17
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2019
A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancerNatasha C Lucki, Genaro R Villa, Naja Vergani, et al.
Diabetes|October 9, 2013
Podocyte-specific GLUT4-deficient mice have fewer and larger podocytes and are protected from diabetic nephropathyJohanna Guzman, Alexandra N Jauregui, Sandra Merscher-Gomez, et al.
Journal of the American Chemical Society|July 1, 2024
On Demand Bioorthogonal Switching of an Antibody-Conjugated SPECT Probe to a Cytotoxic Payload: from Imaging to TherapyPragya Adhikari, Guangmin Li, MaryAnn Go, et al.
NAM Perspectives|September 30, 2022
The Promise of Digital Health: Then, Now, and the FutureAmy Abernethy, Laura Adams, Meredith Barrett, et al.
Neuron|November 5, 2020
A Non-covalent Ligand Reveals Biased Agonism of the TRPA1 Ion ChannelChang Liu, Rebecca Reese, Simon Vu, et al.
Journal of Medicinal Chemistry|July 20, 2016
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung CancersGérald Lelais, Robert Epple, Thomas H Marsilje, et al.
NAM Perspectives|November 2, 2023
Identifying Credible Sources of Health Information in Social Media: Phase 2-Considerations for Non-Accredited Nonprofit Organizations, For-Profit Entities, and Individual SourcesHelen Burstin, Susan Curry, Megan L Ranney, et al.
Journal of Medicinal Chemistry|March 27, 2014
Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacyDean P Phillips, Wenqi Gao, Yang Yang, et al.
Journal of Medicinal Chemistry|November 21, 2017
The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic PropertiesTony Siu, Jason Brubaker, Peter Fuller, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 17, 2025
In an older-age vascular cohort, carotid stenosis is associated with processing speed and executive function cognitive deficits, which correlate with p-tau217Summan Zahra, Scott R French, Juan C Arias, et al.
Pageof 17